Reverse mergers have returned with a bang. More biotechs have taken this back door to the public markets so far in 2026 than ...
The Society for Clinical Research Sites (SCRS) has launched a data intelligence platform to offer fresh insights into how ...
Lycia Therapeutics is banking on a $227.8 million IPO as the biotech seeks to finance its pipeline of protein degraders for ...
Rapport's phase 2 bipolar win strikes chord with analysts despite falling short of original ambition
Rapport Therapeutics’ phase 2 bipolar mania study has hit its primary endpoint, furthering the biotech’s efforts to make RAP-219 a multi-indication blockbuster. However, the effect size fell short of ...
Medtech M&A reached its highest level in more than a decade, EY found, with a total disclosed deal value of roughly $130 ...
Nano24’s inhaled exosome therapy reduced respiratory failure in patients with acute respiratory distress syndrome (ARDS), ...
Amid the Chinese biopharma licensing boom, Hengrui Pharmaceuticals stands out from the crowd. | Amid the Chinese biotech ...
Ambrose Healthcare has bought AM-Pharma for up to 161 million euros ($181 million), inking a cut-price deal for the Dutch ...
Oracle kicked off the year by launching its Oracle Life Sciences AI Data Platform, which it touted as using generative AI, ...
Last Friday, Frazier Life Sciences hit the Nasdaq with its second biotech-focused SPAC. TCGX is already on the hunt for ...
Nouscom has reeled in 120 million euros ($135 million) in series D funds to take a cancer-preventing vaccine through a ...
AbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial. Skyrizi is a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results